EGFR and neoplasm: Additionally, CD109’s interaction with EGFR could amplify pro-inflammatory cytokine production, such as IL-6 and IL-8, by activating downstream pathways like Akt/mTOR and NF-κB, thereby enhancing tumor growth, immune suppression, and potentially contributing to chemoresistance.